Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7909097 | 0.94 | TSHR (0.41) | TSHRALDH1A1CYP1A2CYP2C9LMNA | |
| SCHEMBL7909105 | 0.94 | TSHR (0.41) | TSHRALDH1A1CYP1A2CYP2C9LMNA | |
| SCHEMBL8045333 | 0.94 | TSHR (0.39) | TSHRALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL7915493 | 0.90 | TSHR (0.36) | TSHRALDH1A1 | |
| SCHEMBL7915501 | 0.90 | TSHR (0.36) | TSHRALDH1A1 | |
| SCHEMBL7915496 | 0.90 | TSHR (0.36) | TSHRALDH1A1 | |
| SCHEMBL7915488 | 0.90 | TSHR (0.36) | TSHRALDH1A1 | |
| SCHEMBL7909226 | 0.88 | TSHR (0.37) | TSHRALDH1A1CYP1A2LMNAMAPK1 | |
| SCHEMBL7909232 | 0.88 | TSHR (0.37) | TSHRALDH1A1CYP1A2LMNAMAPK1 | |
| SCHEMBL7909218 | 0.88 | TSHR (0.37) | TSHRALDH1A1CYP1A2LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020015804-A1 | LIQUID-CRYSTAL COMPOUNDS, LIQUID-CRYSTAL COMPOSITION CONTAINING THE SAME, AND LIQUID-CRYSTAL DISPLAY ELEMENT CONTAINING THE SAME | CHISSO CORPORATION (JP) | 2002-02-07 | — | — | US | disclosed |
| EP-0976703-A1 | LIQUID-CRYSTAL COMPOUNDS, LIQUID-CRYSTAL COMPOSITION CONTAINING THE SAME, AND LIQUID-CRYSTAL DISPLAY ELEMENT CONTAINING THE SAME | CHISSO CORPORATION (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020015804-A1 | LIQUID-CRYSTAL COMPOUNDS, LIQUID-CRYSTAL COMPOSITION CONTAINING THE SAME, AND LIQUID-CRYSTAL DISPLAY ELEMENT CONTAINING THE SAME | CXCR1, CCR1, CXCR2 | TSHR 2972/4885ALDH1A1 1317/4885CYP1A2 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.